Home › Mipsagargin Demonstrates Clinical Benefit In Subset Of Glioblastoma Patients
 

Keywords :   


Mipsagargin Demonstrates Clinical Benefit In Subset Of Glioblastoma Patients

2015-12-02 02:02:20| drugdiscoveryonline Home Page

GenSpera Inc., a biotech company developing a novel prodrug therapeutic for the treatment of cancer, recently announced results from the Phase II study investigating the use of mipsagargin (G-202) for the treatment of glioblastoma multiforme

Tags: benefit patients clinical demonstrates

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.11Spain fines budget airlines including Ryanair 179m
22.11Eastern North Pacific Tropical Weather Outlook
22.11Atlantic Tropical Weather Outlook
22.11Rush PANTS
22.11SBS
22.11/
22.11 YOU
22.11
More »